Charles River rapid cell banking programs are now being offered by Charles River Laboratories International, Inc. (NYSE: CRL), which announced the offering from Wilmington, Massachusetts, on September 17, 2026, through Business Wire. The company says the platform is designed to accelerate release timelines so that biopharmaceutical and advanced therapy developers can reach critical milestones faster and bring innovative treatments to patients sooner.
The headline figure is a 40% reduction in cell bank production timeline against an industry standard of 20 weeks, according to the company’s announcement. Charles River did not publish a revised week-by-week schedule, a price list or customer examples in the release, so those details are labeled as not disclosed in this report.
The offering combines rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS). Charles River describes the combination as a comprehensive, end-to-end solution intended to improve product quality, safety and regulatory readiness while reducing overall development timelines.
Charles River Rapid Cell Banking: What the Programs Deliver
In practical terms, Charles River rapid cell banking pairs two capabilities that developers often handle in sequence: establishing a cell bank, and then characterizing it to support safety and quality claims. The company positions the pairing as a way to expedite pre-bank and release testing while still generating the characterization data needed for regulatory submissions.
Matthew Hewitt, Corporate Vice President and Chief Technology Officer, Manufacturing at Charles River, attributed the speed gain to the company’s long-standing expertise in rapid test methods. He said integrating rapid banking with NGS helps accelerate critical milestones and de-risk development programs, calling it a “powerful advantage for developers.”
At every stage, Charles River says it provides deep regulatory rigor and support, helping clients navigate the complexities of biologic and advanced therapy development and align with global regulatory expectations as programs progress from early development through commercialization. The release does not name specific clients, products or programs that have used the service.
The announcement is a company statement of capability rather than a clinical or peer-reviewed result, and the 40% figure is the company’s own claim. Developers evaluating the service should request program-specific timelines directly from Charles River before building them into development plans.
TABLE 1: Charles River Rapid Cell Banking Announcement at a Glance
| Attribute | Detail |
|---|---|
| Company | Charles River Laboratories International, Inc. |
| Ticker | NYSE: CRL |
| Dateline | Wilmington, Mass. |
| Release date | Sep. 17, 2026 |
| Distribution | Business Wire |
| Offering | Rapid cell banking programs with rapid cell bank and release packages plus NGS characterization |
| Claimed timeline reduction | 40% in cell bank production timeline |
| Stated industry standard | 20 weeks |
| Resulting timeline in weeks | Not disclosed (arithmetic from the stated figures implies about 12 weeks; this is an editorial calculation, not a company statement) |
| Pricing | Not disclosed |
| Named customers | Not disclosed |
| Availability by site | Not disclosed |
How Charles River Rapid Cell Banking Uses Rapid Test Methods
The first lever in Charles River rapid cell banking is the use of rapid microbiological methods (RMM) for microbial detection, including Celsis ATP-Bioluminescence technology. The company says these approaches replace traditional compendial testing with automated, objective results, which in turn produce faster pre-bank and release testing timelines.
A second rapid method is mycoplasma detection using real-time PCR. Together, the RMM and PCR-based assays form what Charles River calls its established expertise in delivering rapid test methods. The release does not state assay turnaround times in days, so the accompanying table lists the testing elements without time figures.
Because pre-bank and release testing sit on the path to a usable cell bank, the company’s argument is that shortening those steps shortens the overall production timeline. That reasoning is consistent with the 40% reduction claim, though the press release does not break the saving down by individual test or by stage of the process.
TABLE 2: Testing Methods Named in the Charles River Release
| Method | Purpose | Technology Named | Stage | Turnaround Time |
|---|---|---|---|---|
| Rapid microbiological methods (RMM) | Microbial detection | Celsis ATP-Bioluminescence | Pre-bank and release testing | Not disclosed |
| Rapid mycoplasma detection | Mycoplasma detection | Real-time PCR | Pre-bank and release testing | Not disclosed |
| NGS in vitro characterization | Cell bank characterization, pathogen and broad viral detection | iDTECT platform | After cell bank establishment | Not disclosed |
NGS and iDTECT: Charles River Rapid Cell Banking Characterization
For Charles River rapid cell banking customers, characterization follows the establishment of the cell banks. The company says it can apply NGS through its iDTECT platform to provide reliable in vitro characterization services. Colette Côté, Executive Director and Scientific Advisor, Global Biologics Testing Services, said NGS is “transforming how the industry approaches safety and quality testing.”
The company adds that NGS has transformed genetic analysis and pathogen detection through its scalability, speed and broad viral detection capabilities. Côté said that combining rapid banking with NGS as part of the characterization package helps clients shorten timelines while generating comprehensive data to support regulatory submissions and strengthen confidence in product quality and safety.
Charles River’s CGMP-compliant NGS testing services are described as meeting global regulatory expectations for accuracy, reliability and compliance, including GMP requirements and guidance from the FDA and EMA along with ICH Q5A and Q5B. These standards frame the characterization component of Charles River rapid cell banking. The release also cites the acquisition of Pathoquest, which it calls a recognized leader in NGS solutions for in vitro characterization and quality control testing of biopharmaceutical products, and says integrating its technology platform delivers faster, more advanced sequencing-based testing. Transaction terms and integration status were not disclosed.
TABLE 3: Regulatory Frameworks and NGS Capabilities Cited by Charles River
| Item | What the Release States | Disclosure Status |
|---|---|---|
| CGMP-compliant NGS testing | Accelerates development timelines without compromising safety | Stated |
| GMP requirements | Cited as a standard the NGS services meet | Stated |
| FDA and EMA guidance | Cited as regulatory guidance the NGS services meet | Stated |
| ICH Q5A and Q5B | Cited as guidance the NGS services meet | Stated |
| Pathoquest acquisition | Strengthens NGS capabilities for in vitro characterization and quality control testing | Terms, date and integration status not disclosed |
| NGS attributes | Scalability, speed, broad viral detection capabilities | Stated |
Charles River Rapid Cell Banking, AMAP and the 3Rs
The announcement ties the offering to the company’s commitment to the 3Rs: Replacement, Reduction and Refinement. Charles River says the platform advances that commitment through its Alternative Methods Advancement Project (AMAP), which develops and implements alternative methods and other innovative strategies to reduce reliance on animal testing while supporting efficient product development. Charles River rapid cell banking is therefore presented as both a speed story and a 3Rs story.
AMAP is a Charles River-led initiative focused on New Approach Methodologies (NAMs) and other scientific and technological solutions aimed at reducing dependence on traditional animal testing. The company says AMAP is supported by a global, cross-functional Scientific Advisory Board led by Dr. Namandjé N. Bumpus.
Charles River describes itself as a provider of essential products and services that help pharmaceutical and biotechnology companies, government agencies and leading academic institutions accelerate research and drug development. Its stated focus spans discovery, early-stage development and the safe manufacture of new therapies for patients.
